Cargando…
TLR7 Agonist GS–9620 Combined with Nicotinamide Generate Viral Reactivation in Seronegative SHIV(SF162P3)-Infected Rhesus Monkeys
Antiretroviral therapy is capable of inhibiting HIV replication, but it fails to completely achieve a cure due to HIV persistence. The commonly used HIV cure approach is the “shock and kill” strategy, which employs latency-reversing agents to trigger viral reactivation and boost cellular immunity. F...
Autores principales: | Cong, Zhe, Sun, Yuting, Dang, Cui, Yang, Chenbo, Zhang, Jingjing, Lu, Jiahan, Chen, Ting, Wei, Qiang, Wang, Wei, Xue, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295986/ https://www.ncbi.nlm.nih.gov/pubmed/37371802 http://dx.doi.org/10.3390/biomedicines11061707 |
Ejemplares similares
-
Molecular Determinants of GS-9620-Dependent TLR7 Activation
por: Rebbapragada, Indrani, et al.
Publicado: (2016) -
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016) -
Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge
por: Eugene, Hermancia S, et al.
Publicado: (2013) -
Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018) -
Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIV(SF162P3N) molecular clones in rhesus macaques
por: Ren, Wuze, et al.
Publicado: (2013)